Devices/Safety Alert·openFDA/device

FREESTYLE LIBRE 2 PLUS (ABBOTT DIABETES CARE INC) — Malfunction

MediumPublished Apr 30, 2026· AI-analyzed May 19, 2026View original FDA source

AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.

What happened

A malfunction event was reported regarding the FreeStyle Libre 2 Plus, a device manufactured by Abbott Diabetes Care Inc.

Who it affects

This report primarily affects Abbott Diabetes Care Inc., healthcare providers prescribing the FreeStyle Libre 2 Plus, and regulatory/QA professionals monitoring the safety profile of continuous glucose monitoring (CGM) systems.

Why it matters

The reporting of a malfunction in a CGM system signifies a failure of the device to meet performance specifications during use. While the source does not specify the nature of the malfunction or any associated patient harm, regulatory professionals should interpret this as part of the ongoing post-market safety profile monitoring for this product class, which may necessitate internal CAPA reviews if similar malfunctions emerge.

Practical takeaway

QA and vigilance teams should review internal malfunction reports for this device family to determine if this event represents an isolated failure or a trending performance issue. Ensure post-market surveillance records are updated to reflect the nature of the reported malfunction.

FDA source material

Event type: Malfunction. Device: FREESTYLE LIBRE 2 PLUS by ABBOTT DIABETES CARE INC.

Open in openFDA / FDA.gov

AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.

FREESTYLE LIBRE 2 PLUS (ABBOTT DIABETES CARE INC) — Malfunction

More from Devices